GenomeScan^® OncoPair

Matched Sequencing. Clearer Answers. Smarter Treatment

What is OncoPair?

OncoPair is a high-resolution, ISO/IEC 17025-accredited sequencing solution that distinguishes inherited (germline) mutations from acquired (somatic) ones. By comparing tumor DNA to a matched normal reference, OncoPair filters out background noise and reveals tumor-specific mutations with exceptional accuracy.

This matched design empowers researchers and clinicians to:

Identify actionable mutations with confidence
Design targeted therapies based on unique somatic profiles
Accelerate clinical trial readiness with reproducible, high-quality data

Whether you’re advancing immunotherapies, tracking tumor evolution, or refining patient stratification, OncoPair provides the genomic clarity to drive research forward—fast and confidently.

Note: OncoPair is for research use only and not intended for clinical diagnostics.

How can I help you?

Connect with Stefanie, our Head of Oncology

Sample type required:

Tumor Samples

FFPE (Formalin-Fixed Paraffin-Embedded)
Fresh Frozen Tissue

Matched Normal Samples

Blood
Saliva
Adjacent healthy Tissue

Key Documents

Service Specification Sheet

Sample Submission Guide

Actionable genomic insights start with GenomeScan^® OncoPair.

Designed for Challenging Samples

Real-world clinical material is often limited or degraded. OncoPair is optimized for:

FFPE and Fresh Frozen Tissues
Rare or Archival Tumor Samples

This makes it ideal for retrospective studies, rare cancer types, and difficult-to-source specimens.

Ultra-Deep Sequencing

Our platform delivers comprehensive genomic profiling with:

1 Billion Paired-End Reads per Tumor Sample (WGS)
300 Million Paired-End Reads for Matched Normal Tissue (WGS)

This depth enables robust detection of somatic variants, structural alterations, and CNVs, even from FFPE samples.

Tissue Contamination Control

Accurate somatic variant detection starts with high tumor purity. GenomeScan^® OncoPair ensures data integrity through:
- Certified Pathologist Review: Every sample undergoes tumor cell percentage (TCP) assessment to validate tumor content.
- Targeted Microdissection: When needed, microdissection enriches tumor regions, enhancing analytical precision and reducing noise from surrounding tissue.

Seamless Integration with Clinical Workflows

GenomeScan^® OncoPair operates under ISO/IEC 17025 accreditation, meeting the highest standards for:

Technical Competence
Reproducibility
Regulatory Compliance

Comprehensive Variant Spectrum

GenomeScan^® OncoPair delivers a complete view of the tumor’s genomic landscape, capturing the full spectrum of clinically relevant alterations in a single, streamlined workflow.

Single Nucleotide Variants (SNVs)
Detect point mutations that may drive oncogenesis or influence treatment response.
Insertions and Deletions (Indels)
Identify small genomic changes that can disrupt gene function or regulatory elements.
Copy Number Variants (CNVs)
Reveal amplifications and deletions across the genome, including key cancer driver genes.
Structural Variants (SVs)
Detect large-scale rearrangements such as translocations, inversions, and duplications—critical for understanding tumor evolution and resistance mechanisms.

Transforming Tumor Genomics with OncoPair’s PCGR Reporting

Turning complex genomic data into clear clinical insights is essential for precision oncology. With GenomeScan^® OncoPair, you have the option to include Personalized Cancer Genome Reporter (PCGR), a powerful reporting tool that transforms variants into annotated information.

Therapeutic Relevance
Annotates tumor-specific variants with links to databases, such as the NCBI or EBI database.
Visual Summaries and Clinical Annotations
Includes intuitive graphics, variant classifications, and evidence levels to support fast interpretation by clinical teams.
Transparent and Reproducible Reporting
Built with curated databases, ensuring consistency and traceability across projects.

Whether you’re preparing for clinical trials or conducting translational research, PCGR reporting adds clarity, confidence, and clinical relevance to your genomic data.

Image copyright Personal Cancer Genome Reporter (PCGR). Sigve Nakken

Workflow: From Sample to Actionable Mutations

GenomeScan^® OncoPair delivers a robust, end-to-end sequencing pipeline designed to ensure high data quality and biological relevance at every stage—from sample intake to clinically actionable insights.

Technical Specifications Overview

The following table outlines the key parameters for tumor and matched normal sample processing:

Applications in Clinical Trials

OncoPair leverages tumor–normal genome comparison to accurately identify somatic mutations, enabling deeper insights into cancer biology and treatment response.

Cancer Driver Gene Discovery

Identifies true cancer-driving mutations by filtering out inherited variants, revealing key mechanisms of tumorigenesis and potential therapeutic targets.

Drug Response and Resistance Analysis

Detects mutations associated with drug sensitivity and acquired resistance, including secondary mutations that arise during treatment, to guide therapy adjustments.

Comprehensive Tumor Profiling

Delivers a complete view of genomic alterations — SNVs, indels, CNVs, MNPs and structural variants — across the entire genome for robust clinical interpretation.

Patient Stratification

Pinpoints actionable mutations and biomarkers to support inclusion in specific clinical trial arms, improving precision medicine and trial efficiency.

Neoantigen Prediction

Enables accurate identification of tumor-specific peptides for personalized cancer vaccine development and immunotherapy strategies.

Service Specifications Sheet

We have summarized key information about our OncoPair service into a service specification sheet.

Download sheet

Explore our oncology portfolio

Whole Genome Sequencing

Whole Exome Sequencing

Ultra low input Transcriptomics

FFPE tissue RNA sequencing

Genetic QC

Long-read sequencing

Contact us today!

Fill out the form below or reach out directly to our Head of Oncology, Stefanie,at oncology@genomescan.nl— we’ll get back to you shortly to discuss how we can support your project.

GenomeScan^® OncoPair

What is OncoPair?